Acquiring Company
Lantheus Holdings
Acquired Company
Life Molecular Imaging
Bedford
FarehamBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareDescription
Lantheus Holdings, Inc. has completed the acquisition of Life Molecular Imaging Limited for $350 million. This acquisition enhances Lantheus's capabilities in Alzheimer's disease diagnostics through the addition of Neuraceq, an F-18 PET imaging agent. The announcement was made on July 21, 2025. Despite recent stock performance declines, analysts remain optimistic about Lantheus's growth.
Other recent acquisitions in Therapeutics and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- Supernus acquires SAGE Therapeutics for USD 8.50/share (July 31, 2025)
- AbbVie to acquire Capstan Therapeutics (July 15, 2025)
- AbbVie to acquire Capstan Therapeutics for $2.1B, $2.1B (June 30, 2025)
- Exicure, Inc. acquires GPCR USA for cancer therapy expansion (June 27, 2025)
- Novartis to acquire Tourmaline Bio for $1.4B, $1.4B (September 9, 2025)
Who to call at Lantheus Holdings, and when
When Lantheus Holdings changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Lantheus Holdings raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lantheus Holdings, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lantheus Holdings. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lantheus Holdings makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Life Molecular Imaging?
Life Molecular Imaging was acquired by Lantheus Holdings, based in Bedford. The deal was reported on July 27, 2025. Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Lantheus Holdings is publicly traded (LNTH) and operates in Biotechnology.
When did Lantheus Holdings acquire Life Molecular Imaging?
Lantheus Holdings's acquisition of Life Molecular Imaging was reported on July 27, 2025. Lantheus Holdings, Inc. has completed the acquisition of Life Molecular Imaging Limited for $350 million. This acquisition enhances Lantheus's capabilities in Alzheimer's disease diagnostics through the addition of Neuraceq, an F-18 PET imaging agent. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Life Molecular Imaging do?
Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. It is privately held, operating in Biotechnology, and is based in Fareham.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.